스마트 불임 추적기 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the smart fertility trackers market size is expected to increase from USD 1.62 billion in 2025 to USD 1.71 billion in 2026 and reach USD 2.63 billion by 2031, growing at a CAGR of 9.03% over 2026-2031.

This report is Segmented by Product Type (Wearable Fertility Trackers, and More), Biomarker (Luteinizing Hormone, and More), Connectivity Model (App & Proprietary Device, and More), End Use (Trying To Conceive, Natural Contraception, and More), Sales Channel (Direct-To-Consumer Brand Websites, E-Commerce Marketplaces, Pharmacies and Retail, Clinics), and Geography. The Market Forecasts in Value (USD).

Global Smart Fertility Trackers Market Trends and Insights

Rising Infertility Prevalence And Delayed Parenthood

Wider use of digital tracking aligns with later family planning timelines, which increases the need to pinpoint fertile windows with greater certainty. In the smart fertility trackers market, regulatory progress and platform expansion help convert intent into adoption by reducing friction across devices and care pathways. Cross-wearable integrations extend access to clinically cleared contraceptive algorithms for smartwatch owners, creating a conversion funnel without added hardware purchases. At-home multi-hormone systems that generate numeric readouts promote more informed cycle management and allow users and clinicians to track trends over multiple cycles. Standardized billing codes for digital contraception lower hurdles to reimbursement and employer coverage, which supports continued category growth as benefits teams look for cost-effective options.

Rapid Shift To At-Home, App-Connected Fertility Testing

The smart fertility trackers market continues to shift toward quantitative, at-home panels that deliver lab-like results within minutes. One example is a wireless multi-hormone reader that uses dual fluorescence and colorimetric sensing to produce numerical concentrations that correlate closely with blood serum and confirm ovulation with high precision, with results syncing directly to mobile apps. Recognition from major consumer technology forums further validates user demand for integrated systems that measure multiple hormones in a single session and fit within daily routines. App ecosystems increasingly combine device data with education and coaching, and they now link to broader wellness platforms, which support continuous engagement across cycle phases. As the smart fertility trackers market integrates hormones, biometrics, and software services, user expectations evolve toward clear, numeric insights and actionable guidance rather than simple calendar estimates.

Privacy/Regulatory Scrutiny Of Fertility Apps And Data Handling

Data handling remains a visible concern for users who expect strong controls on reproductive health information. The smart fertility trackers market is sensitive to privacy signals, which influences trust and churn across paid and free offerings. Regional frameworks differ on consent and scope, so vendors that operate in multiple jurisdictions often design toward stricter baselines to avoid rework and build user confidence. Product claims also interact with oversight because contraception, diagnosis, and wellness have different regulatory definitions that determine evidence standards and marketing limits. These dynamics make clear disclosures and consent models an important part of product design, app onboarding, and customer support in 2026. Vendors that address privacy up front tend to see stronger retention and advocacy, which supports sustainable growth in the category.

Other drivers and restraints analyzed in the detailed report include:

1. Wearable Integrations Enabling Overnight Temperature Capture
2. Employer Fertility Benefits And HSA/FSA Eligibility Broaden Access
3. Clinical Validity Limits Of Single-Parameter Approaches

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Wearable fertility trackers held a 32.34% share in 2025, reflecting strong user preference for passive, overnight sensing tied to cycle insights. The smart fertility trackers market continues to benefit from integrations that bring cleared fertility algorithms to popular smartwatch platforms, which convert existing device owners into app subscribers without requiring a new dedicated tracker purchase. At-home multi-hormone analyzers are projected to grow at an 11.32% CAGR through 2031 as users and clinicians prioritize numeric hormone data for more precise timing and cycle assessment. One platform recognized at a global consumer electronics forum highlighted at-home lab-quality testing for multiple hormones in a single 16-minute session, with early users reporting a stronger understanding of symptoms that map to their hormone curves. As quantitative systems mature, connected ovulation tests and connected basal thermometers keep a mid-tier position, although margin pressure rises as fully integrated solutions cut manual data entry and bundle insights with coaching.

The smart fertility trackers market also reflects growing diversity across devices and software. A new wireless reader introduced in 2026 uses dual fluorescence and colorimetric sensing to deliver high-precision hormone results that correlate well with venous assays, with built-in connectivity for seamless app sync. App-only options remain a lower-cost entry point for cycle tracking and education, yet they face higher churn when accuracy or personalization falls short of user expectations. Vendors that pair hardware with software strengthen recurring revenue via test-strip refills and premium subscriptions, while open wearable integrations offer a lower-cost path to scale by tapping into large installed bases. With clearer evidence and more robust user support, quantitative analyzers are positioned to lead premium adoption, while wearables define convenience at scale. These dynamics shape growth paths for both vertical bundles and open-platform strategies in the smart fertility trackers market.

Luteinizing hormone represented a 35.67% biomarker share in 2025, supported by its role as the most familiar signal for imminent ovulation. Progesterone-metabolite tracking is the fastest-growing biomarker with a 10.87% CAGR through 2031 as users and clinicians look to confirm ovulation and assess luteal sufficiency with quantitative signals. In the smart fertility trackers market, multi-hormone systems present a fuller picture by tracking estrogenic rise, LH surge, and post-ovulation progesterone changes as a single curve, which enables more targeted timing and clearer diagnostics. Readers that combine fluorescence and colorimetric imaging produce stable numeric baselines and trend lines that reduce interpretation errors common in yes or no strips. As more platforms link hormone results to algorithmic insights, users gain clearer, day-by-day guidance across the follicular and luteal phases.

Wearables that monitor temperature and related biometrics add value by passively capturing ovulatory patterns between at-home tests, and peer-reviewed analyses support higher pooled accuracy for multi-parameter approaches over temperature-only methods. In practice, the smart fertility trackers market is moving toward biomarker fusion, where hormone panels anchor confirmation and wearables fill gaps with continuous context. Vendors that present hormone and biometric data together in an app workflow make it easier for users to interpret signals and for clinicians to review longitudinal trends. This integrated approach helps reduce false positives and missed windows, which supports conversion to paid tiers. As quantitative accuracy and user experience improve, biomarker strategies that balance depth and convenience will continue to gain share in the smart fertility trackers market.

Geography Analysis

North America holds a leading position with a 43.45% revenue share in 2025, supported by coverage progress and third-party wearable integrations that allow scale without new hardware. The smart fertility trackers market size reflects that base and continues to grow in 2026 as cleared contraceptive algorithms connect to watch platforms and gain billing pathways for simpler reimbursement. Canada's 2024 approval extended access to a large audience for non-hormonal digital contraception, which pairs well with the region's high smartphone and wearable penetration. In 2026, user expectations center on accuracy, privacy, and ecosystem fit, which favor platforms that provide numeric hormone data or validated biometric fusion. Clinic-linked models also emerge as complements where specialist guidance supports TTC users and complex cases.

Asia-Pacific is the fastest-growing region at a 12.82% CAGR through 2031, powered by mobile-first behavior and expanding marketplace infrastructure that makes cross-border fulfillment easier for consumers and sellers. The smart fertility trackers market gains from verified-supplier programs and logistics support that reduce import friction and elevate trust for first-time buyers. As price sensitivity remains a factor in many APAC markets, open wearable integrations provide a path to adoption using devices users already own. In 2026, vendors are tailoring SKUs, language packs, and education content for local contexts to raise conversion and retention. Hybrid strategies that combine marketplace reach with owned app communities are becoming standard as brands scale regionally.

Europe holds steady with emphasis on privacy-by-design and clinical clarity. The smart fertility trackers market share for companies that secure regional approvals and maintain transparent data practices is rising as users weigh accuracy claims alongside privacy expectations. Integrations that enable contraception and conception support across major watch ecosystems continue to raise awareness and lower setup friction. The Middle East and Africa, along with South America, are early in the adoption curve yet show meaningful momentum where marketplaces improve delivery reliability and customer support. In 2026, region-specific partnerships with clinics and women's health providers are helping align products with local standards and care pathways, which supports durable expansion in the smart fertility trackers market.

1. AccuQuik
2. Apple
3. Ava
4. Daysy
5. Fairhaven Health
6. Femometer
7. Garmin
8. Inito Inc.
9. Mira
10. Modern Fertility (Ro)
11. NaturalCycles Nordic AB
12. Oura Health
13. OvuSense
14. Ovy
15. PREGMATE
16. Premom (Easy@Home)
17. Proov
18. SPD Swiss Precision Diagnostics
19. Tempdrop
20. Wondfo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Infertility Prevalence And Delayed Parenthood
  • 4.2.2 Rapid Shift to At-Home, App-Connected Fertility Testing
  • 4.2.3 Wearable Integrations Enabling Overnight Temperature Capture
  • 4.2.4 Employer Fertility Benefits and HSA/FSA Eligibility Broaden Access
  • 4.2.5 AI-Powered Multi-Parameter Tracking Improves Accuracy and Usability
  • 4.2.6 D2C and E-Commerce Scale Global Reach for Smart Trackers
• 4.3 Market Restraints
  • 4.3.1 Privacy/Regulatory Scrutiny of Fertility Apps and Data Handling
  • 4.3.2 Clinical Validity Limits of Single-Parameter Approaches
  • 4.3.3 Subscription and Device Lock-In Raise Total Cost of Ownership
  • 4.3.4 Platform/Regulatory Limits on Contraceptive Claims
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Wearable Fertility Trackers
  • 5.1.2 Connected Ovulation Test Systems
  • 5.1.3 Connected Basal Thermometers
  • 5.1.4 At-home Multi-hormone Analyzers
  • 5.1.5 App-only Fertility/Contraceptive Solutions
• 5.2 By Biomarker
  • 5.2.1 Luteinizing Hormone
  • 5.2.2 Estrogen Metabolites
  • 5.2.3 Progesterone Metabolite
  • 5.2.4 Basal/Skin Temperature
  • 5.2.5 Others (HRV and respiratory rate, Multi-parameter fusion)
• 5.3 By Connectivity Model
  • 5.3.1 App & Proprietary Device
  • 5.3.2 App & Third-party Wearable Integration
  • 5.3.3 Standalone App
• 5.4 By End Use
  • 5.4.1 Trying to conceive (TTC)
  • 5.4.2 Natural contraception
  • 5.4.3 Cycle Health Tracking and Insights
• 5.5 By Sales Channel
  • 5.5.1 Direct-to-Consumer Brand Websites
  • 5.5.2 E-commerce marketplaces
  • 5.5.3 Pharmacies and Retail
  • 5.5.4 Clinics
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 AccuQuik
  • 6.3.2 Apple Inc.
  • 6.3.3 Ava
  • 6.3.4 Daysy
  • 6.3.5 Fairhaven Health
  • 6.3.6 Femometer
  • 6.3.7 Garmin
  • 6.3.8 Inito Inc.
  • 6.3.9 Mira
  • 6.3.10 Modern Fertility (Ro)
  • 6.3.11 NaturalCycles Nordic AB
  • 6.3.12 Oura Health
  • 6.3.13 OvuSense
  • 6.3.14 Ovy
  • 6.3.15 PREGMATE
  • 6.3.16 Premom (Easy@Home)
  • 6.3.17 Proov
  • 6.3.18 SPD Swiss Precision Diagnostics
  • 6.3.19 Tempdrop
  • 6.3.20 Wondfo

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment